Skip to main content

Table 1 Baseline characteristics of the 26 patients enrolled

From: Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Characteristics

Number (%) of patients

Age (approximately at consent)

  

 Median (range)

64.5

(34–81 years)

Gender

  

 Male

14

54%

 Female

12

46%

ECOG performance status

  

 ECOG 0

8

31%

 ECOG 1

18

69%

Primary tumour types

  

 Colorectal cancer

8

31%

 Endometrial cancer

3

12%

 Small intestine cancer

3

12%

 Stomach cancer

3

12%

 Bile duct cancer

3

12%

 Breast cancer

2

8%

 Pancreatic cancer

1

4%

 Prostate cancer

1

4%

 Neuroendocrine cancer

1

4%

 Glioblastoma

1

4%

Number of prior systemic therapy linesa

  

 No previous lines

1

4%

 1 previous line

10

38%

 2 previous lines

7

27%

  ≥ 3 previous lines

8

31%

Lynch syndrome

8

33%

  1. Percentages may not equal 100% due to rounding
  2. Abbreviations: ECOG Eastern Cooperative Oncology Group
  3. aNumber of prior systemic therapy lines is the sum or prior lines of hormonal therapy, chemotherapy and targeted-therapy